New antibody drug CT-202 enters first human trials for tough cancers
Disease control
Not yet recruiting
This early-stage study tests a new drug called CT-202 in people with advanced triple negative breast, colorectal, or urothelial cancers that have come back or spread. The drug is designed to help the immune system attack cancer cells. The main goals are to check safety and find t…
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC